{
  "id": "63eeefc5f36125a426000009",
  "type": "factoid",
  "question": "What is targeted by CIS43LS?",
  "ideal_answer": "CIS43LS is a monoclonal antibody that targets Plasmodium falciparum.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
    "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
    "http://www.ncbi.nlm.nih.gov/pubmed/33332286"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum infection in a phase 1 clinical trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum infection in healthy adults in Mali over a 6-month malaria season.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: CIS43LS was protective against P. falciparum infection over a 6-month malaria season in Mali without evident safety concerns. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on these data, CIS43LS has advanced to phase I clinical trials, and AAV delivery provides a potential next-generation approach for malaria prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Plasmodium falciparum"
}